Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alcon files travoprost/timolol combo

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA has accepted Alcon's NDA for a fixed combination of travoprost 0.004%/timolol 0.5% (TTFC) for the treatment of glaucoma, the firm announces Jan. 25. According to preliminary data presented at the Royal Hawaiian Eye Meeting in January, TTFC reduced intraocular pressure 2 mmHg more than travoprost alone at 8 a.m. in one study. In two other Phase III studies, TTFC was not statistically different from concomitant therapy at the 8 a.m. time points "and at most of, but not all, the other measured time points." Safety was comparable to concomitant dosing in all three studies. The firm estimates approximately 50% of U.S. glaucoma patients use two or more agents...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002458

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel